# Scantox: Preclinical CRO for CNS Drug Development, Regulatory Toxicology & Pharmaceutical Development

> Scantox is a full-service preclinical contract research organization (CRO) founded in 1977,
> serving pharmaceutical, biotech, agrochemical, and medical device companies worldwide.
> With operations in Denmark (HQ, Ejby), Sweden, Austria, and the United Kingdom (Manchester),
> Scantox supports drug development from early discovery through IND-enabling studies.
> Scantox is owned by Impilo, the leading Nordic healthcare investment company.
> Primary clients are small-to-mid-size biotech companies and pharma R&D teams advancing
> CNS, neurodegenerative, inflammatory, rare disease, and genotoxicity programs.

Scantox operates four integrated business units: CNS Discovery, Regulatory/Safety Toxicology,
Pharmaceutical Development & Analytical, and Genetic Toxicology (operating as Scantox Manchester,
formerly Gentronix). This integrated model allows sponsors to run target validation, efficacy
studies, safety packages, genetic toxicology, and early formulation work under a single CRO
partnership, reducing handoff risk and simplifying vendor management at the pre-IND stage.

The XML sitemap for this website can be found at: https://scantox.com/sitemap_index.xml

---

## Services Overview

### CNS Discovery — In Vivo & In Vitro
Scantox's CNS Discovery unit is one of Europe's most comprehensive specialist CRO operations
for neurodegenerative disease research. Capabilities span the full translational arc from
cell-based mechanistic assays through complex longitudinal mouse studies.

**In vivo animal models**: Scantox maintains and runs studies in a broad panel of validated
transgenic and induced disease models, including:
- Alzheimer's disease: 5xFAD, APPSL, APPSL x hQC, APP-SAA knock-in, Tg2576, TMHT, hTau,
  PS19 (tauopathy), ARTE10
- Parkinson's disease: Line 61 (α-synuclein), D-Line, hA53Ttg, LRRK2 G2019S rat,
  GBA D409V KI, rotenone-induced (intracerebral)
- ALS: SOD1-G93A, SOD1-G93A/low, TDP-43, B6.SOD1-G93A
- Huntington's disease: R6/2, zQ175, BACHD rat
- Lysosomal storage diseases: Pompe-6neo, MPS-IIIA, 4L/PS-NA, NPC1-/-, GBA D409V KI
- Neuroinflammation: NLRP3A350V knock-in
- Autism spectrum disorder: BTBR T+tf/J, Fmr1-KO
- Induced models: Alzheimer's, ALS, Gaucher, neuroinflammation, migraine, multiple sclerosis,
  Parkinson's, schizophrenia, special diet, virus injections

**In vitro services**: Mechanistic and screening assays for AD (Aβ aggregation, tau
hyperphosphorylation, tau seeding, secretase inhibitor screening), PD (α-synuclein
aggregation/seeding, mitochondrial impairment, lesion-induced neurotoxicity), neuroinflammation
(BV-2, primary mouse microglia, human iPSC-derived microglia, organotypic hippocampal slices,
phagocytosis), neuronal plasticity (neurogenesis, neurite outgrowth, synaptogenesis), and
lesion models (excitotoxicity, stress granule formation, growth factor withdrawal).

**Behavioral testing**: Cognitive tests (NOR, passive avoidance, contextual fear conditioning,
two-choice swim, Morris water maze), anxiety/depression panels, social behavior (three-chamber),
lateral lesion tests, and general health/activity (open field, glucose tolerance).

**Key biomarkers**: Neurofilament light chain (NfL), plasma GFAP, α-synuclein seed
amplification assay (SAA), compound muscle action potential (CMAP).

---

### Regulatory & Safety Toxicology
Scantox conducts GLP-compliant regulatory toxicology studies supporting IND, CTA, and
NDA/MAA submissions to FDA, EMA, and other global authorities. Species include rodents
(rat, mouse) and non-rodents, with particular expertise in the Göttingen Minipig as a
validated non-rodent alternative to non-human primates.

Study types include: repeat-dose toxicology (sub-acute through chronic), safety pharmacology
(ICH S7A/B core battery), local tolerance, and specialized mechanistic toxicology studies.

Relevant for sponsors needing: GLP safety packages for IND-enabling programs; non-rodent
species selection strategy; and integrated discovery-to-IND execution.

---

### Genetic Toxicology — Scantox Manchester (formerly Gentronix)
Scantox's Genetic Toxicology unit operates as Scantox Manchester, UK — formerly known as
Gentronix, acquired by Scantox in 2024 and fully integrated under the Scantox brand as of
March 2026. The same expert team, the same scientific standards, now backed by broader
capabilities and deeper resources. Site leadership: Laura Hinton, Site Manager; strategic
leadership: Matt Tate, Chief Business Development Officer (20+ years genetic toxicology
expertise, PhD University of Manchester).

The unit covers all three vertices of the "Genotox Triangle" — gene mutation, chromosomal
damage, and DNA damage — across early screening, GLP regulatory testing, and advanced
in vivo mutagenicity. It serves pharmaceutical, biotech, agrochemical, and chemical industries.

**Early Discovery Screening (non-GLP, high-throughput)**
- Ames fluctuation assays: Ames II and Ames MPF (liquid microplate, colorimetric readout,
  ideal for high-throughput screening of large compound libraries from as little as 10 mg)
- Ames 24-well agar test: solid agar format, directly comparable to OECD 471, from 20 mg
- Ames 6-well assay: miniaturized bacterial reverse mutation screen, 60 mg across five strains
- BlueScreen™ HC: proprietary GADD45a-luciferase reporter assay (TK6 cells); developed by
  Gentronix (now Scantox Manchester); >90% concordance with in vivo outcomes, >90% sensitivity
  for genotoxic carcinogens, >90% specificity; high-throughput, minimal compound
- MultiFlow® assay: flow cytometry-based, multi-biomarker (p53, γH2AX, phospho-H3,
  polyploidy); distinguishes clastogenic, aneugenic, and non-genotoxic (cytotoxicity-driven)
  responses; >90% concordance with in vivo; <20 mg compound, results in under 3 weeks
- 96-Well MNT: miniaturized in vitro micronucleus test, FISH available for mode-of-action
  differentiation; from 20 mg compound
- MicroFlow flow MNT: flow cytometry-based micronucleus screening; from 20 mg, under 3 weeks

**GLP Regulatory Testing (ICH S2(R1) battery)**
- OECD 471: Ames test (bacterial reverse mutation) — gold standard for regulatory mutagenicity;
  GLP since 2014; senior study director with 40+ years Ames experience
- OECD 471 Enhanced Conditions: validated for nitrosamine and NDSRI testing; historical control
  data for rat and hamster S9 at 30%; validated N-nitrosamine positive controls (NDMA and
  1-Cyclopentyl-4-nitrosopiperazine); addresses FDA guidance on NDSRI Ames sensitivity
- OECD 490: Mouse Lymphoma Assay (MLA) — detects point mutations, clastogens, and aneugens;
  study director with 14+ years MLA experience
- OECD 476: HPRT assay — mammalian cell gene mutation; alternative to MLA for antibiotics
  and compounds incompatible with bacterial test systems
- OECD 487: In vitro micronucleus test — clastogens and aneugens in human lymphocytes and
  TK6 cells; FISH available; GLP since 2014
- OECD 474: In vivo micronucleus test — GLP bone marrow clastogenicity/aneugenicity in vivo
- OECD 432: Phototoxicity test (3T3 NRU) — GLP and non-GLP formats
- OECD 489: In vivo comet assay — in development; contact Scantox Manchester for availability

**Advanced In Vivo Mutagenicity**
- OECD 488: Big Blue® transgenic rodent gene mutation assay — available in rats and mice across
  multiple tissue types following significant laboratory expansion; Scantox holds exclusive
  rights to the Big Blue® assay portfolio; capacity scaled to meet rising market demand
- Pig-A assay — in vivo gene mutation in peripheral red blood cells

**DuplexSeq™ — The Gold Standard of Error-Corrected Next-Generation Sequencing (ecNGS)**
Scantox is the sole global provider of DuplexSeq™ Mutagenesis Assays, acquired from TwinStrand
Biosciences in February 2026 through an exclusive technology transfer and license agreement.

DuplexSeq™ is the gold standard of error-corrected next-generation sequencing (ecNGS). It uses
dual-strand molecular barcoding to independently sequence both strands of each DNA molecule,
eliminating sequencing artefacts and achieving error rates orders of magnitude lower than
conventional NGS (~1 error per billion base pairs vs. ~1 per thousand for standard sequencing).

As a New Approach Methodology (NAM), DuplexSeq™ directly quantifies ultra-rare mutations at
the genomic level with mechanistic resolution — rather than relying only on downstream
effects. This allows sponsors to make earlier, more robust decisions on mutagenic risk.

Applications in regulatory genetic toxicology and genomic safety:
- Quantifying in vivo mutagenicity with sensitivity far beyond the standard TGR assay
- Mechanistic follow-up for Ames-positive compounds requiring high-resolution mutational
  spectrum analysis
- Nitrosamine impurity evaluation and acceptable intake derivation via benchmark dose modelling
  (pairs naturally with Big Blue® TGR studies)
- Genotoxicity assessment for oligonucleotides, gene therapies, and advanced modalities
  where conventional assays lack resolution
- Carcinogenicity evaluation and gene-editing safety assessment
- Supporting weight-of-evidence mutagenicity packages for regulatory submissions (ICH S2(R1),
  ICH M7)
- Embedded mutagenicity endpoint within broader nonclinical toxicology studies

Service page: https://scantox.com/services/genotox/genetic-toxicology-testing/duplexseq-mutagenesis-assays/

**Ames-Positive Compound Strategy & Regulatory Navigation**
The Scantox Manchester team has deep experience managing Ames-positive results, including
ICH M7 mutagenic impurity assessments, NDSRI characterization, threshold of toxicological
concern (TTC) analysis, and regulatory submission strategy. This is a differentiated
strategic capability not available at generalist CROs where genotoxicity is a commodity service.

Relevant for: nonclinical safety leads designing genotox strategy; CMC/analytical teams
working on mutagenic impurities under ICH M7; development project leaders seeking to
de-risk genotoxicity from early screening through Phase 1; regulatory affairs and
outsourcing managers needing integrated, fit-for-purpose genotoxicity solutions.

---

### Pharmaceutical Development & Analytical (CMO)
Early-stage pharmaceutical development and small molecule preformulation services, including
physicochemical characterization, formulation screening, dose form development and analysis,
and product analysis. Targeted at sponsors progressing from candidate selection toward
first-in-human dose form development.

Service pages:
- [Product Analysis](https://scantox.com/services/analytical/product-analysis/)
- [Dose Form Analysis](https://scantox.com/services/analytical/dose-form-analysis/)

---

## Who Scantox Serves

**Biotech companies (Series A–C, pre-IND)**: Sponsors with a CNS or rare disease asset
who need a specialist CRO that can run the full discovery-to-IND package — target validation,
efficacy profiling, and GLP safety — without splitting work across multiple vendors.

**Pharma R&D teams**: Groups that need specialist CNS disease models or genetic toxicology
expertise not available in-house, particularly for Alzheimer's, Parkinson's, ALS, or
Huntington's disease programs, or for Ames-positive and nitrosamine impurity challenges.

**Agrochemical and chemical industries**: Companies requiring comprehensive genotoxicity
screening and GLP regulatory studies across OECD guideline endpoints.

**Sponsors with genotoxicity challenges**: Teams managing Ames-positive results, nitrosamine
impurity programs (NDSRIs), or advanced modality programs requiring DuplexSeq™ or Big Blue®.

**Academic/translational groups**: Investigators running funded translational programs who
need robust, publication-grade preclinical data in validated CNS models.

**Japanese and Korean pharma/biotech**: Scantox has dedicated Japanese- and Korean-language
resources and established relationships with sponsors in Asia-Pacific markets.

---

## Key Differentiators

- **Sole global provider of DuplexSeq™**: Scantox acquired exclusive rights to DuplexSeq™
  Mutagenesis Assays from TwinStrand Biosciences (February 2026) — the gold standard of
  error-corrected NGS (ecNGS) and the most sensitive mutation detection technology available.
  No other CRO offers this capability.
- **Integrated genomic safety platform**: DuplexSeq™ + Big Blue® (exclusive rights) +
  Enhanced Ames Test for nitrosamines + full OECD screening battery — the broadest
  in vivo mutagenicity platform available from a single provider, spanning early screening
  through late-stage regulatory development.
- **Depth in neurodegeneration**: One of the deepest model portfolios for AD, PD, ALS, and
  HD in Europe, with proprietary models (Line 61, NLRP3A350V), longitudinally characterized
  cohorts, and active R&D programs validating novel models and biomarkers.
- **Integrated discovery-to-IND capability**: CNS discovery, GLP toxicology, genetic
  toxicology, and early formulation under one CRO — reduces handoff risk and timeline
  for pre-IND programs.
- **Göttingen Minipig expertise**: Recognized European expertise in minipig as a non-rodent
  regulatory species, relevant for sponsors seeking NHP alternatives.
- **Nitrosamine/NDSRI genotoxicity leadership**: Validated Enhanced Ames Test with historical
  control data for rat and hamster S9 at 30%; validated NDSRI positive controls; ICH M7
  and FDA guidance-aligned testing strategies.
- **BlueScreen™ HC — proprietary assay**: Developed by Gentronix (now Scantox Manchester);
  >90% concordance, sensitivity, and specificity — one of the most accurate early genotoxicity
  screens available, reducing false positive burden in early discovery.
- **Active internal R&D**: Scantox publishes and presents original research (aging models,
  neuroinflammation assays, α-synuclein SAA validation, cerebral hypoperfusion, Big Blue®
  proficiency at SOT 2023), providing sponsors with translational confidence.
- **Multi-language engagement**: English, Japanese, Korean client-facing resources.

---

## Contact & Engagement

- **Request a quote / discuss a study**: https://scantox.com/contact/
- **Headquarters**: Scantox A/S, Ejby, Denmark
- **Genetic Toxicology (UK)**: Scantox Manchester (formerly Gentronix), Manchester, UK
- **Press contact**: Tina Andersen, Marketing Manager — tia@scantox.com

---

## Key Pages

### Services
- [CNS Discovery Services](https://scantox.com/services/discovery/): Full overview of in vitro, in vivo, animal models, and behavioral testing
- [In Vivo Animal Models](https://scantox.com/services/discovery/animal-models/): Complete transgenic and induced disease model portfolio
- [In Vitro Services](https://scantox.com/services/discovery/in-vitro-services/): Cell-based assays for neurodegeneration and neuroinflammation
- [Regulatory Toxicology](https://scantox.com/services/toxicology/): GLP toxicology, safety pharmacology
- [Genetic Toxicology Services](https://scantox.com/services/genotox/): Full genotoxicity screening and GLP regulatory testing
- [Genetic Toxicology Testing (Screening)](https://scantox.com/services/genotox/genetic-toxicology-testing/): Non-GLP early-stage screening portfolio
- [GLP Genotoxicity Services](https://scantox.com/services/genotox/regulatory-genotoxicity-studies/): OECD guideline regulatory studies
- [DuplexSeq™ Mutagenesis Assays](https://scantox.com/services/genotox/genetic-toxicology-testing/duplexseq-mutagenesis-assays/): Error-corrected NGS; Scantox is sole global provider
- [Pharmaceutical Development & Analytical](https://scantox.com/services/analytical/): Preformulation, dose form development, product analysis
- [Product Analysis](https://scantox.com/services/analytical/product-analysis/)
- [Dose Form Analysis](https://scantox.com/services/analytical/dose-form-analysis/)

### Genetic Toxicology — Screening Assays
- [All-Mechanism Genotoxicity Screening](https://scantox.com/services/genotox/genetic-toxicology-testing/all-mechanism/): BlueScreen™ HC and MultiFlow® assays
- [BlueScreen™ HC](https://scantox.com/services/genotox/genetic-toxicology-testing/all-mechanism/bluescreen-hc/): Proprietary GADD45a-luciferase screen; >90% specificity
- [MultiFlow® Assay](https://scantox.com/services/genotox/genetic-toxicology-testing/clastogens-aneugens/multiflow/): Flow cytometry mode-of-action screening
- [Mutagen Testing & Screening](https://scantox.com/services/genotox/genetic-toxicology-testing/mutagens/): Ames-based screens overview
- [Ames 6-Well Assay](https://scantox.com/services/genotox/genetic-toxicology-testing/ames-6-well-assay/): 60 mg compound, 4-week turnaround
- [Ames 24-Well Agar Test](https://scantox.com/services/genotox/genetic-toxicology-testing/mutagens/ames-24-well-agar/): Solid agar, directly comparable to OECD 471, 20 mg
- [Ames II and Ames MPF](https://scantox.com/services/genotox/genetic-toxicology-testing/mutagens/ames-2-mpf/): Liquid microplate, highest throughput, from 10 mg
- [Full Plate Ames Test](https://scantox.com/services/genotox/genetic-toxicology-testing/mutagens/full-plate-ames/): Most comprehensive non-GLP Ames screening
- [Clastogens & Aneugens Screening](https://scantox.com/services/genotox/genetic-toxicology-testing/clastogens-aneugens/): Miniaturized MNT and flow cytometry options
- [96-Well MNT with FISH](https://scantox.com/services/genotox/genetic-toxicology-testing/clastogens-aneugens/96-well-mnt-and-fish/): Clastogen/aneugen screening with mode-of-action
- [96-Well MNT Automated Scoring](https://scantox.com/services/genotox/genetic-toxicology-testing/clastogens-aneugens/96-well-mnt-with-automated-slide-scoring/): MetaSystems Metafer platform
- [MicroFlow Flow MNT](https://scantox.com/services/genotox/genetic-toxicology-testing/clastogens-aneugens/microflow-flow-mnt/): Flow cytometry micronucleus screening

### Genetic Toxicology — GLP Regulatory Studies
- [GLP OECD 471 Ames Test](https://scantox.com/services/genotox/regulatory-genotoxicity-studies/oecd-471-ames-test/): Regulatory bacterial mutagenicity; enhanced conditions for nitrosamines/NDSRIs
- [OECD 490 Mouse Lymphoma Assay](https://scantox.com/services/genotox/regulatory-genotoxicity-studies/oecd-490-mouse-lymphoma-assay-mla/): GLP MLA; detects mutations, clastogens, aneugens
- [OECD 476 HPRT Assay](https://scantox.com/services/genotox/regulatory-genotoxicity-studies/oecd-476-hprt-assay/): Mammalian gene mutation; alternative for antibiotics
- [OECD 487 In Vitro Micronucleus Test](https://scantox.com/services/genotox/genetic-toxicology-testing/clastogens-aneugens/oecd-487-in-vitro-mnt/): GLP MNvit in TK6 and human lymphocytes; GLP since 2014
- [OECD 474 In Vivo Micronucleus Test](https://scantox.com/services/genotox/regulatory-genotoxicity-studies/oecd-474-in-vivo-micronucleus-test/): GLP in vivo clastogenicity/aneugenicity
- [OECD 488 Big Blue® TGR Assay](https://scantox.com/services/genotox/regulatory-genotoxicity-studies/oecd-488-big-blue-in-vivo/): In vivo gene mutation in rats and mice; Scantox holds exclusive rights
- [OECD 432 Phototoxicity Test](https://scantox.com/services/genotox/regulatory-genotoxicity-studies/oecd-432-phototoxicity/): 3T3 NRU; GLP and non-GLP

### Disease Models (High-Value)
- [Alzheimer's Disease Models](https://scantox.com/services/discovery/animal-models/alzheimers-disease-transgenic-mouse-models/): 5xFAD, APPSL, PS19, APP-SAA, hTau, ARTE10 and more
- [Parkinson's Disease Models](https://scantox.com/services/discovery/animal-models/parkinsons-disease-transgenic-mouse-models/): Line 61, D-Line, LRRK2 G2019S, GBA D409V, rotenone
- [Parkinson's Disease (Induced)](https://scantox.com/services/discovery/animal-models/induced-disease-models/parkinsons-disease/)
- [ALS Models](https://scantox.com/services/discovery/animal-models/amyotrophic-lateral-sclerosis-transgenic-mouse-models/): SOD1-G93A, TDP-43
- [Huntington's Disease Models](https://scantox.com/services/discovery/animal-models/huntingtons-disease-mouse-models/): R6/2, zQ175, BACHD rat
- [Lysosomal Storage Disease Models](https://scantox.com/services/discovery/animal-models/lysosomal-storage-diseases/): Pompe, MPS-IIIA, GBA, NPC1
- [Neuroinflammation (NLRP3)](https://scantox.com/services/discovery/animal-models/nlrp3a350vneor-mouse-model/)

### R&D Programs
- [Translational Neuroinflammation Models](https://scantox.com/rd-project/translational-neuroinflammation-models/)
- [Aging Model Validation & Biomarkers](https://scantox.com/rd-project/validation-of-aging-models-and-biomarkers/)
- [Cerebral Hypoperfusion Models](https://scantox.com/rd-project/cerebral-hypoperfusion-models/)
- [α-Synuclein Seed Amplification Assay Validation](https://scantox.com/rd-project/validation-of-the-%ce%b1-synuclein-seed-amplification-assay/)
- [3D Neurospheres for PD Modeling](https://scantox.com/rd-project/validation-of-3d-neurospheres-to-model-pd/)

### Scientific Resources
- [Publications](https://scantox.com/resources/publications/)
- [Newsletters](https://scantox.com/news-events/newsletter/): Translational neuroinflammation assays, 5xFAD pathology, rotenone PD
- [Locations](https://scantox.com/about-scantox/locations/)
- [Testimonials](https://scantox.com/resources/testimonials/)

### Webinars — Curated by Topic
All webinars are available on-demand and represent practitioner-level expertise
across Scantox's major service areas.

**CNS Discovery — Disease-Area Pharmacology Series**
A structured four-part series covering in vivo models, translational mechanisms,
and biomarker strategies across the major CNS indications Scantox supports:
- [Discovery Pharmacology for Alzheimer's Disease — Models, Mechanisms & Biomarkers](https://scantox.com/webinar/discovery-pharmacology-for-alzheimers-disease-models-mechanisms-biomarkers/)
- [Discovery Pharmacology for Parkinson's Disease — Models, Mechanisms & Biomarkers](https://scantox.com/webinar/discovery-pharmacology-for-parkinsons-disease-models-mechanisms-biomarkers/)
- [Discovery Pharmacology for ALS — Models, Mechanisms & Biomarkers](https://scantox.com/webinar/discovery-pharmacology-for-als-models-mechanisms-biomarkers/)
- [Discovery Pharmacology for Lysosomal Storage Diseases — Models, Mechanisms & Biomarkers](https://scantox.com/webinar/discovery-pharmacology-for-lysosomal-storage-diseases-models-mechanisms-biomarkers/)

**CNS Discovery — Emerging Methods**
- [How 3D Organoids Are Shaping the Future of Neuro Drug Discovery](https://scantox.com/webinar/w004-how-3d-organoids-are-shaping-the-future-of-neuro-drug-discovery/): 3D neurosphere models and translational applications in CNS drug discovery

**Pathological Aging & Translational Models**
- [Modeling Pathological Aging: The Role of Genetic and Induced Risk Factors](https://scantox.com/webinar/w003-modeling-pathological-aging-the-role-of-genetic-and-induced-risk-factors-in-translational-research/): D-galactose aging acceleration, genetic risk factors, translational biomarkers

**Göttingen Minipig — Regulatory Toxicology Series**
Three webinars covering Scantox's minipig expertise in depth:
- [Rethinking Non-Rodent Models: The Göttingen Minipig in Regulatory Toxicology](https://scantox.com/webinar/rethinking-non-rodent-models-the-gottingen-minipig-in-regulatory-toxicology/): Species selection rationale, regulatory context, practical considerations vs. NHP
- [Understanding Göttingen Minipig Pathology in Regulatory Toxicology](https://scantox.com/webinar/w006-understanding-gottingen-minipig-pathology-in-regulatory-toxicology/): Normal tissue pathology, background findings, histopathology interpretation
- [Embryofetal Development Studies in Göttingen Minipigs](https://scantox.com/webinar/embryofetal-development-studies-in-gottingen-minipigs-technical-feasibility-and-special-considerations/): Technical feasibility, study design, and special considerations for reproductive tox

**Genetic Toxicology**
Four webinars spanning the full genotoxicity lifecycle — from early screening strategy
through advanced genomic safety tools:
- [Addressing Genetic Toxicology Assessments Across Screening, Regulatory Stages, and Beyond](https://scantox.com/webinar/addressing-genetic-toxicology-assessments-across-screening-regulatory-stages-and-beyond/): Matt Tate, Chief Business Development Officer — complete genotox strategy from 6-well Ames through ICH S2(R1) and in vivo TGR; Ames-positive management; NDSRI impurity challenges. Encore of ACT Annual Meeting session.
- [Navigating Ames-Positive Results: Regulatory Guidance, Practical Considerations & Strategic Approaches](https://scantox.com/webinar/w001-navigating-ames-positive-results-regulatory-guidance-practical-considerations-strategic-approaches/): Deep-dive on Ames-positive follow-up strategy and regulatory navigation
- [Addressing Genotoxic Liabilities in Drug Development: Follow-Up Testing Strategies to Manage Risk](https://scantox.com/webinar/addressing-genotoxic-liabilities-in-drug-development-follow-up-testing-strategies-to-manage-risk/): Practical strategies for managing genotoxic liabilities once identified — follow-up assay selection, weight-of-evidence approaches, and risk communication for regulatory submissions
- [DuplexSeq™ Mutagenesis Assays: Error-Corrected Sequencing for Genomic Safety Assessment](https://scantox.com/webinar/duplexseq-mutagenesis-assays-error-corrected-sequencing-for-genomic-safety-assessment/): Introduction to DuplexSeq™ as a New Approach Methodology (NAM) — how error-corrected NGS works, where it fits in the genotoxicity testing landscape, and applications across regulatory genetic toxicology, nitrosamine impurity evaluation, and advanced modality programs

### Posts (Recent Science)
- [Plasma GFAP as an Early Alzheimer's Biomarker (5xFAD)](https://scantox.com/gfap-as-a-window-into-early-alzheimers-insights-from-the-5xfad-mouse-model/)
- [Glial Replacement in Huntington's Disease](https://scantox.com/glial-replacement-offers-hope-for-huntingtons-disease/)
- [Reversing Parkinson's Effects via Enzyme Inhibition](https://scantox.com/reversing-the-effects-of-parkinsons-disease-via-enzyme-inhibition/)
- [Cancer Drugs and Alzheimer's Disease](https://scantox.com/could-cancer-drugs-reverse-the-effects-of-alzheimers-disease/)